We are inspiring human belief in a healthier world
Our founding mission is to make highly quality medicines affordable and accessible to the world
30 years of Service in the pharmaceutical industry, backed by proven track record in R&D excellence
Our mission to enable access to affordable medicines and improve lives flow from the top
Expanding our presence to serve more people and create meaningful impact
Being acknowledged for our efforts motivates our entire team
Our expertise across APIs, global generics, biosimilars and custom pharmaceutical services is secured by a strong R&D backbone
We have steadily invested in a wide range of innovations to make our product portfolio diverse and differentiated in a competitive market
The path to serving patients better
World-class and differentiated portfolio in chronic therapy areas
Achieving a sustainable health equity
Fully integrated services across the value chain
Committed to transforming standards of care
Researching areas of unmet medical need
Our expertise rest on the pillars of our advanced R&D capabilities, world-class manufacturing facilities, our long legacy of trust and our partnerships
Research excellence for us means to invest in the future of health for the world
We invest in cutting edge research to develop new cures for challenging diseases
Built to world-class standards, our facilities enable us to produce high-quality and affordable medicines
Legacy of trust
Growing better, together
We are committed to making a positive impact by contributing to healthy communities and leading a responsible business
Aiming for a sustainable environment
A constant focus on sustainable environment with focus on health and safety
A steadfast commitment to enable communities
Hetero aims to report comprehensively and transparently for all stakeholders
Find range of resources including press releases, featured stories and information on social media channels
Access our latest press releases and resources for News and Media section
Discover the stories that enumerate the way we understand disease and develop medicines
Latest media releases and statements in the Hetero newsroom
Browse and download multimedia resources for use
Notices
Back
~ Hetero to market the anti-Covid drug under the brand name ‘Tocira’
India, Hyderabad; 06th September, 2021: Hetero, a globally renowned vertically integrated pharmaceutical organization announced today that the Drug Controller General of India (DCGI) has issued for restricted use, Emergency Use Authorization (EUA) for the generic version of Tocilizumab in India. This authorization will enable the medical practitioners to use the generic drug Tocilizumab for the treatment of Covid-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Dr. B. Partha Saradhi Reddy, Chairman, Hetero Group said:“We are pleased with the approval of Hetero’s Tociluzumab (Tocira) in India. This demonstrates our technical capabilities and commitment to bringing important therapeutics relevant to COVID care. This approval is extremely crucial for supply security in India considering a global shortage of Tociluzumab. We will be working closely with the Government to ensure equitable distribution.”
Hetero’s TOCIRA (Tocilizumab) will be marketed by its associate company ‘Hetero Healthcare’ in India with the support of its strong distribution network across the country.
Hetero’s biologics arm ‘Hetero Biopharma’ will be manufacturing the drug at its dedicated biologics facility, based at Jadcherla in Hyderabad, India.
Hetero’s Tocilizumab 400mg/20ml is the biosimilar version of Roche’s Actemra/RoActemra ®, and will be available from September end.
About Hetero
Hetero is a globally renowned vertically integrated pharmaceutical organization engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.
Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.
Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.
For more information on Hetero, please visit www.heteroworld.com.
For further details, please contact: Fortuna PR
Vishal Kumar Mobile: 98855 85802 Email: vishal@fortunapr.com
Priya K Mobile: 95354 25418 Email: priya@fortunapr.com